Sunday, 22 November 2026 Every SEC filing alert, by company
ALFAFINDER USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · FY 2026

Azenta FY 2026 Results: Net Loss of $167M, Loss Widens

Azenta, Inc. transitioned to a pure-play life sciences company following the divestiture of its semiconductor business in 2022 and its B Medical Systems business in July 2026. The company is currently undergoing a leadership transition with an interim CEO and has initiated a restructuring plan in its Multiomics segment to consolidate its North American laboratory network and improve operating efficiency.

FY 2026 at a glance · $ million · annual
MetricFY 2026FY 2025
Revenue621.7593.8
Gross profit275.0270.3
Profit before tax-151.0-7.1
Net income-167.0-55.8
EPS (diluted, $ a share)$-3.70$-1.22

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+4.7%
Gross margin44.2%
Operating margin-28.1%
Source

10-K filed with the SEC, NASDAQ: AZTA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Azenta, Inc.: key numbers

Share price
$44.80Close, Nov 20
Market cap
$1.98B
Shares outstanding
41.94MLatest SEC cover page
Sector
Technology
Industry
Special Industry Machinery, NECSIC 3559

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Azenta, Inc.

All →
4:47 PM ET 8-K
Financial Results

Azenta Financial Results

Azenta reported fiscal fourth quarter and full year 2026 results, with Q4 revenue growing 5% year-over-year to $167 million. The company completed the sale of its B Medical Systems business during the year and is focusing on driving organic growth and profitability in its Multiomics and Sample Management segments for fiscal 2027.

Term
FY2026

“We closed fiscal 2026 with improving momentum, delivering stronger performance in the second half of the year. Our businesses have strong market positions and differentiated capabilities, and we are seeing progress from our efforts to improve commercial execution and operating efficiency.”

Dr. Martin Madaus, Interim President and Chief Executive Officer

“Fiscal 2027 is about consistent execution and accelerating performance. We are focused on driving organic growth, expanding profitability and cash generation, and executing on our strategic initiatives.”

Dr. Martin Madaus, Interim President and Chief Executive Officer
8:03 AM ET 8-K
M&A Deal

Azenta Signs $71M M&A Deal with SynPlexity Inc.

Azenta acquired SynPlexity Inc., a synthetic biology company specializing in high-throughput gene libraries, and entered into an exclusive licensing and supply agreement with Elegen Corp. for its cell-free DNA manufacturing technology. The combined strategic investments involve an expected capital deployment ranging from $32 million to $71 million to expand Azenta's GENEWIZ gene synthesis capabilities and regional production capacity.

Value
$71M
Counterparty
SynPlexity Inc.
Term
5 years
8:01 AM ET 8-K
Business Update

Azenta Business Update

Azenta, Inc. announced a restructuring plan for its Multiomics segment involving workforce reductions and the closure of three North American laboratory sites. The company expects to incur pre-tax charges between $11 million and $13 million, including $9 million in asset impairments, while targeting $11 million in annualized cost savings.

3:49 PM ET 8-K
Executive Compensation

Azenta Executive Compensation

Azenta, Inc. entered into a letter agreement with Dr. Martin D. Madaus setting his compensation as Interim President and CEO, including a $600,000 base salary, a 100% cash performance bonus, and $1.2 million in restricted stock units. Additionally, the company approved one-time RSU retention awards for other named executive officers, including $1.0 million for CFO Lawrence Lin.

Counterparty
Dr. Martin D. Madaus
Term
1 year

Get Alerts

Get ALFAFINDER USA alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.